Sensorion (FRA:RFM) ROCE %: -50.58% (As of Dec. 2025)


FRA:RFM Sensorion SA FRA:RFM
24 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is Sensorion ROCE %?

Sensorion FRA:RFM -4.28% 24 ROCE % is -50.58% as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sensorion's annualized ROCE % for the quarter that ended in Dec. 2025 was -50.58%.

Sensorion  (FRA:RFM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sensorion ROCE % Related Terms

Sensorion ROCE % Historical Data

* Premium members only.

The historical data trend for Sensorion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion ROCE % Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.69 -62.35 -69.56 -45.48 -48.07

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.43 -44.21 -29.10 -47.33 -50.58
FRA:RFM
24GF Score
Sensorion SA FRA:RFM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion ROCE % Calculation

Sensorion's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-29.214/( ( (89.277 - 13.653) + (57.887 - 11.966) )/ 2 )
=-29.214/( (75.624+45.921)/ 2 )
=-29.214/60.7725
=-48.07 %

Sensorion's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-26.554/( ( (73.338 - 14.264) + (57.887 - 11.966) )/ 2 )
=-26.554/( ( 59.074 + 45.921 )/ 2 )
=-26.554/52.4975
=-50.58 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -50.58% mean?
Sensorion (FRA:RFM) has a ROCE % of -50.58% as of Dec. 2025.
Is Sensorion's ROCE % too high?
Sensorion's current ROCE % is -50.58%. Overall, Sensorion has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's ROCE % compare to VRTX and REGN?
Sensorion's ROCE % of -50.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sensorion's current ROCE % is -50.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current ROCE % of -50.58%. The current ROCE % is -50.58%. Sensorion's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current ROCE % is -50.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
24GF Score

Get the complete analysis for FRA:RFM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price